NCT02913443View on ClinicalTrials.gov

A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

October 24, 2017

Study Completion Date

October 24, 2017

Conditions
Small Cell Lung Cancer
Interventions
DRUG

RO7051790

RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.

Trial Locations (8)

2100

Rigshospitalet; Onkologisk Klinik, København Ø

28041

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid

28050

Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid

35233

University of Alabama at Birmingham, Birmingham

94805

Institut Gustave Roussy, Villejuif

K1H 8L6

The Ottawa Hospital Cancer Centre; Oncology, Ottawa

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02913443 - A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | Biotech Hunter | Biotech Hunter